Solid momentum of the new drugs, Ozempic and Saxenda, helped Novo Nordisk achieve another healthy quarterly performance, while the insulin woes only furthered. The Biopharmaceuticals clocked growth too, but more due to one-time benefits. Guidance for the year, in effect, was upgraded. Approval of oral semaglutide remains the next biggest catalyst, in addition to any corporate action that the company has been considering for a long time.
13 Aug 2019
New products (and one-offs) drive guidance upgrade
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
New products (and one-offs) drive guidance upgrade
Novo Nordisk A/S Class B (NNO2:WBO) | 0 0 2.2% | Mkt Cap: 611,927m
- Published:
13 Aug 2019 -
Author:
Kamla Singh -
Pages:
3
Solid momentum of the new drugs, Ozempic and Saxenda, helped Novo Nordisk achieve another healthy quarterly performance, while the insulin woes only furthered. The Biopharmaceuticals clocked growth too, but more due to one-time benefits. Guidance for the year, in effect, was upgraded. Approval of oral semaglutide remains the next biggest catalyst, in addition to any corporate action that the company has been considering for a long time.